- Home
- TWN vs RIGL Comparison
TWN vs RIGL Comparison
Compare TWN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TWN | RIGL |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.8M | 564.7M |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TWN | RIGL |
|---|---|---|
| Price | $92.77 | $38.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 48.6K | ★ 325.8K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $84.07 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $44.01 | $18.24 |
| 52 Week High | $105.09 | $52.24 |
Technical Indicators
Market Signals| Indicator | TWN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 78.67 |
| Support Level | $88.51 | $33.39 |
| Resistance Level | $101.61 | $44.85 |
| Average True Range (ATR) | 4.13 | 1.51 |
| MACD | -0.73 | 0.63 |
| Stochastic Oscillator | 17.44 | 93.97 |
Price Performance
Historical ComparisonAbout TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.